BCM
ABMD

Bayesian Capital Management’s Abiomed Inc ABMD Stock Holding History

Bayesian Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,200
Closed -$465K – 863
2020
Q1 		$465K Buy
+3,200
New +$531K 0.1% 312
2019
Q2 		– Sell
-6,506
Closed -$1.86M – 722
2019
Q1 		$1.86M Buy
+6,506
New +$2.16M 0.36% 81
2018
Q3 		– Sell
-1,621
Closed -$663K – 851
2018
Q2 		$663K Buy
1,621
+221
+16% +$80.1K 0.15% 196
2018
Q1 		$407K Buy
+1,400
New +$355K 0.1% 317

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bayesian Capital Management's ABMD Position: Q2 2020 in Review

Bayesian Capital Management sold out of Abiomed Inc (ABMD) in Q2 2020, closing a stake of 3,200 shares — an estimated $465K sold.

Bayesian Capital Management first reported a position in ABMD in Q1 2018 and held it in 4 quarters. The position peaked at $1.86M in Q1 2019. 460 funds tracked by Wall St. Rank hold ABMD as of Q2 2020.

  • Bayesian Capital Management reported no remaining Abiomed Inc position as of Q2 2020 after selling out during the quarter.
  • Bayesian Capital Management sold 3,200 Abiomed Inc shares in Q2 2020, an estimated $465K.
  • Bayesian Capital Management first reported a position in Abiomed Inc in Q1 2018 and held it in 4 quarters.
  • Bayesian Capital Management's Abiomed Inc position peaked at $1.86M in Q1 2019.
  • 460 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2020.

Based on Bayesian Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.